Scientists identify novel hereditary prostate cancer type

A groundbreaking study from the University of British Columbia has uncovered a novel hereditary mutation linked to aggressive prostate cancer at an early age. This rare genetic variant, found in the CDK12 gene, presents new possibilities for genetic screening that could revolutionize early detection and intervention for families at heightened risk.

Prostate cancer typically arises from genetic alterations accumulated over a lifetime. However, an estimated 5 to 10 percent of cases are driven by inherited genetic mutations passed down through generations. Mutations in BRCA1 and BRCA2 genes have long been recognized in this context, known for their substantial influence on the risk of breast, ovarian, pancreatic, and prostate cancers. Their identification has already transformed clinical protocols, enabling targeted early screening and prevention strategies.

Published in Cancer Discovery, the new research analyzed genetic profiles of over 4,500 men with aggressive prostate cancer, revealing that a small subset carried germline mutations in CDK12. These five unrelated individuals all developed metastatic prostate cancer between the ages of 44 and 62, underscoring the mutation’s association with severe, early-onset disease. The presence of these mutations prior to cancer development signals a distinct hereditary risk previously unrecognized.

This discovery challenges previous assumptions that harmful CDK12 mutations occur exclusively as spontaneous events in tumor cells, as the study confirmed these variants are heritable. Tumor genomic analyses demonstrated a unique mutational signature indicative of CDK12 loss-of-function, firmly linking the inherited mutations to oncogenesis in these patients.

While inherited CDK12 mutations are rare—estimated at roughly 1 in 1,000 aggressive prostate cancer cases—they may impact hundreds of families worldwide. Identifying even a single carrier enables a cascade effect, allowing relatives to undergo genetic testing and utilize early surveillance to intercept or mitigate disease progression.

The implications for clinical practice are significant, as current genetic testing platforms can readily incorporate CDK12 screening without the need for new technology. This accessibility paves the way for rapid integration of these findings into routine hereditary cancer panels, accelerating the translation from bench to bedside.

Interestingly, the study also raises the possibility that inherited CDK12 mutations elevate ovarian cancer risk. Several prostate cancer patients had familial histories containing ovarian cancer diagnoses, and an additional ovarian cancer patient with a germline CDK12 mutation exhibited similar tumor genetic profiles. This potential link warrants further investigation.

With this advancement, the future of precision oncology looks increasingly promising. Early identification of CDK12 mutation carriers could dramatically improve outcomes by enabling timely, targeted interventions before cancers become metastatic, fulfilling the aspiration that no one dies from an inherited cancer mutation.